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durable control of recurrent respiratory papillomatosis.4,5 Whether these pathways were also
disrupted in the lung tumors of the patient described by Yuan and colleagues was not reported.
Yuan et al. describe a cell-culture technique that
was used to identify specific treatment for recurrent respiratory papillomatosis, but other agents
may also be effective, and caution is advised before broadly using histone deacetylase inhibitors
for recurrent respiratory papillomatosis.
Raj K. Batra, M.D.
Guy W. Soo Hoo, M.D., M.P.H.
Veterans Affairs Greater Los Angeles Healthcare System
Los Angeles, CA
guy.soohoo@va.gov
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of

m e dic i n e

identify a therapy for progressive recurrent respiratory papillomatosis. Although we found that
vorinostat was cytocidal in vitro and clinically effective in vivo, we agree with their comment that
there may be additional therapeutic agents that
our approach might be able to validate. Indeed,
we are currently expanding our studies to explore
such possibilities as well as applying our approach
to nonviral neoplasia. However, we do not agree
with their postulate that a “hit-and-run” mechanism was operative in the patient we described.
Our polymerase-chain-reaction (PCR), reversetranscriptase PCR, and cloning experiments indicate that wild-type and mutant HPV type 11
genomes were present in the laryngeal tumor
and lung tumor, respectively. These findings are
consistent with the well-documented role of HPV
in virtually all cases of recurrent respiratory papillomatosis.1-3
Hang Yuan, Ph.D.
Xuefeng Liu, M.D.
Richard Schlegel, M.D., Ph.D.
Georgetown University Medical Center
Washington, DC
schleger@georgetown.edu
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Hyperosmolar Therapy for Raised Intracranial Pressure
To the Editor: Ropper (Aug. 23 issue)1 recommends the use of mannitol at intervals of 2 to 4 or
more hours to reduce intracranial pressure. Mannitol has been used for four decades to reduce
intracranial pressure without solid evidence of
benefit. In a randomized, controlled trial involving patients with intracerebral hemorrhage, mannitol improved neither the mortality nor the
outcomes at 3 months.2 Mannitol also did not
improve cerebral blood flow as compared with
saline in patients with intracerebral hemorrhage.3
2554

n engl j med 367;26

In a study involving 6 patients with large hemispheric infarctions, mannitol boluses were associated with a clinically significant reduction of
brain volume, which was most marked in the
normal hemisphere.4 In another blinded study,
mannitol administered in a 20% solution in boluses of 1.5 g per kilogram of body weight resulted
in clinical improvement for 30 to 60 minutes in
5 of 12 patients with intracerebral hemorrhage,
without a significant change in horizontal or vertical shift on magnetic resonance imaging.5 Fre-
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quent and large doses of mannitol result in for- Troy E. Dominguez, M.D.
mation of idiogenic osmoles, leading to a reduction Great Ormond Street Hospital
in efficacy and even to rebound brain edema. We London, United Kingdom
No potential conflict of interest relevant to this letter was retherefore think that mannitol should be used ported.
cautiously in patients with raised intracranial
1. Khanna S, Davis D, Peterson B, et al. Use of hypertonic
pressure.
saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury. Crit Care
Usha K. Misra, M.D., D.M.
Med 2000;28:1144-51.
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2. Dominguez TE, Priestley MA, Huh JW. Caution should be
exercised when maintaining a serum sodium level >160 meq/L.
Gourav Goyal, M.D., D.M.
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Lucknow, India
drukmisra@rediffmail.com
No potential conflict of interest relevant to this letter was reported.
1. Ropper AH. Hyperosmolar therapy for raised intracranial

pressure. N Engl J Med 2012;367:746-52.

2. Misra UK, Kalita J, Ranjan P, Mandal SK. Mannitol in intra-

cerebral hemorrhage: a randomized controlled study. J Neurol
Sci 2005;234:41-5.
3. Kalita J, Misra UK, Ranjan P, Pradhan PK, Das BK. Effect of
mannitol on regional cerebral blood flow in patients with intracerebral hemorrhage. J Neurol Sci 2004;224:19-22.
4. Videen TO, Zazulia AR, Manno EM, et al. Mannitol bolus preferentially shrinks non-infarcted brain in patients with ischemic
stroke. Neurology 2001;57:2120-2.
5. Misra UK, Kalita J, Vajpayee A, Phadke RV, Hadique A, Savlani V. Effect of single mannitol bolus in intracerebral hemorrhage. Eur J Neurol 2007;14:1118-23.
DOI: 10.10565/NEJMc1212351

Crit Care Med 2004;32:1438-9.

DOI: 10.1056/NEJMc1212351

To the Editor: Ropper does not mention hyponatremic encephalopathy as a cause of raised intracranial pressure.1 An equation for estimating
the amount of hypertonic saline necessary to increase the serum sodium level is provided, and it
is recommended that biochemical measurements
(levels of serum sodium or serum osmolarity,
blood urea nitrogen, and serum creatinine) be
checked every 8 hours. It is not mentioned that
conditions associated with raised intracranial
pressure are frequently associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and cerebral salt wasting.2 Patients with SIADH and cerebral salt wasting can
have hypertonic urine, with a combined urinary
sodium and potassium concentration greater than
that of plasma. The use of normal saline could
actually result in a decrease in the serum sodium
level, and the use of 3% saline could fail to raise
the serum sodium level as much as calculated.3
A continuous infusion of both normal saline and
3% saline will probably be required to maintain
hyperosmolality, and the serum sodium level
should be checked at least every 4 hours.2 A new
class of drugs, vasopressin antagonists, may have
a role in achieving and maintaining hyperosmolality in patients with raised intracranial pressure.4
Michael L. Moritz, M.D.

To the Editor: Hypertonic saline has been associated with clinically significant renal insufficiency or acute renal failure in pediatric patients
being treated for intracranial hypertension. In one
study, 2 of 10 children being treated with mannitol and hypertonic saline for intracranial hypertension after traumatic brain injury required hemodialysis for renal failure.1 In our study, we
observed an increase in the serum creatinine
level that was two to three times as high as the
baseline level; this increase correlated with an increase in the serum sodium level above 160 mmol
per liter (serum osmolarity, >320 mOsm per liter)
with the use of hypertonic saline (without man- Children’s Hospital of Pittsburgh
nitol) in pediatric patients with intracranial hy- Pittsburgh, PA
pertension and maintenance of a euvolemic hyper- michael.moritz@chp.edu
osmolar state.2 As a result, our pediatric intensive Juan C. Ayus, M.D.
care practitioners will attempt to avoid increas- Renal Consultants of Houston
ing the serum sodium level above 160 mmol per Houston, TX
Drs. Moritz and Ayus report serving as consultants to Otsuka
liter (serum osmolarity, >320 mOsm per liter) Pharmaceuticals. No other potential conflict of interest relevant
when administering hypertonic saline for treating to this letter was reported.
intracranial hypertension in pediatric patients.
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hyponatraemic encephalopathy: an update. Nephrol Dial TransJimmy W. Huh, M.D.
plant 2003;18:2486-91.
Margaret A. Priestley, M.D.
2. Moritz ML. Syndrome of inappropriate antidiuresis and cereUniversity of Pennsylvania Perelman School of Medicine
Philadelphia, PA
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bral salt wasting syndrome: are they different and does it matter?
Pediatr Nephrol 2012;27:689-93.
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To the Editor: Important details regarding mannitol were omitted from Ropper’s article regarding management of elevated intracranial pressure. Ropper asserts that mannitol causes an
osmotic diuresis, therefore increasing the serum
sodium concentration, which leads to water
shifting out of the brain due to an osmotic gradient. The article suggests that kidney function is
necessary for mannitol to reduce intracranial
pressure. However, in our practice, my colleagues
and I have used mannitol (0.25 to 1.0 g per kilogram of body weight intravenously) to control
intracranial pressure in patients with anuric renal failure who are receiving long-term intermittent hemodialysis. In this clinical situation, we
have observed rapid, sustained decreases in intracranial pressure with the administration of mannitol. It is likely that the action of mannitol is due
to increased plasma osmolarity after administration, causing water to shift out of the brain (for
which renal function is not required).1 Other
possible mechanisms for the reduction of intracranial pressure associated with mannitol include
an increase in cerebral perfusion,2 causing cerebral vasoconstriction,3 and decreased production
of cerebrospinal fluid.4 Other physicians may
find, as we have, that the use of mannitol even in
patients with chronic renal failure and elevated
intracranial pressure is beneficial.
Ethan A. Benardete, M.D., Ph.D.
Thomas Jefferson University
Philadelphia, PA
ethan.benardete@jefferson.edu
No potential conflict of interest relevant to this letter was reported.
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The Author Replies: Misra and colleagues eschew the use of mannitol for raised intracranial
pressure. This view may have merit, but they cite
their own randomized trial1 that involved approximately 60 patients, a third of whom had a cerebral hemorrhage smaller than 20 ml in volume
and a third of whom had a cerebral hemorrhage
larger than 40 ml in volume. As I discuss in my
editorial2 on the article by Chesnut et al.3 in this
issue of the Journal, patients with small masses
may not need treatment for intracranial pressure
at all, and there may be a limited benefit to treating those with large lesions, so I am uncertain
whether Misra’s study settles the question of the
usefulness of mannitol. If Misra and colleagues
are questioning entirely the need to reduce intracranial pressure in cerebral hemorrhage, that is
an interesting but separate polemic.
The risks of excessive dehydration in children
are well noted by Huh and colleagues, and I commented in my article that serum sodium levels
over 160 mmol per liter, arbitrarily stated by others
to be the upper limit for safety, have been safely
exceeded in adults.
Hyponatremic encephalopathy is an interesting entity, but in my experience it has not been
obligatorily tied to brain swelling, especially
when the cause is the natriuretic Nelson’s syndrome. The other points made by Moritz and
Ayus are worth noting, and vasopressin antagonists that cause hyperosmolarity are a new prospect as treatment for raised intracranial pressure. An additional issue regarding the correction
of hyponatremia is the risk of “osmotic demyelination” (formerly called “central pontine myelinolysis”) if the level of sodium is made to rise
too rapidly.
In response to the point made by Benardete
about mannitol being effective even in patients
with renal failure: my article indicates that a
“sustained” reduction of intracranial pressure requires osmotic diuresis. I accept that the continued circulation of mannitol in patients with renal
failure might allow a prolonged hyperosmolar
effect until the sugar is metabolized, but repeat
dosing would be required to sustain hyperosmolarity, and chronic renal failure of a degree that
prevents an osmotic diuresis is not typical in
circumstances of raised intracranial pressure.
Benardete is probably aware that the other oftencited effects of mannitol on intracranial pres-
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sure have been minor or transient in clinical
studies.
Allan H. Ropper, M.D.
Brigham and Women’s Hospital
Boston, MA
Since publication of his article, the author reports no further
potential conflict of interest.
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Missing Data in Clinical Trials
To the Editor: Little et al. (Oct. 4 issue)1 mention limiting “the burden and inconvenience of
data collection on the participants” as one of several ideas for limiting missing data in the conduct of clinical trials. Actually, this idea should
be a design feature, and it is also important in
limiting the burden on the investigator (a critical
factor in successful data retrieval as well as patient accrual). Prominent trialists have long championed simple randomized trials for these and
other reasons.2 Simple, minimal data collection
must be one of the most effective strategies for
the prevention of missing data.
This concept is sometimes difficult to sell to
investigators who may envision ancillary studies
and additional publications ensuing from more
data. However, quality trumps quantity, and perhaps this should be made clearer in criteria for
academic promotion.
H. Daniel Lewis, Jr., M.D.
University of Kansas School of Medicine
Kansas City, KS
hdanlewis@earthlink.net

off treatment, and methods are used to address
data that are missing at random, the goal is to
recreate a result that would have been obtained if
patients who discontinued treatment had been
followed after discontinuing treatment. The use
of patients who are receiving treatment to impute
the results for those who have discontinued treatment would seem to be problematic. In addition,
if the common practice of no longer considering
data on patients after treatment discontinuation
is not altered, methods to address missing data
that are based on statistical models will have no
similar patients from whom to model the missing data. How do the authors suggest that we
deal with this conundrum?
Joe Hirman, Ph.D.
Paul Flyer, Ph.D.
Pacific Northwest Statistical Consulting
Woodinville, WA
jhirman@pnwstat.com
No potential conflict of interest relevant to this letter was reported.
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To the Editor: Little and colleagues correctly
point out that missing data are often the result of
study designs that mandate study discontinuation
when treatment is discontinued.1 Intention-totreat inference based on randomization requires
that patient data be collected regardless of treatment status. However, an issue requires further
clarification. When following patients who are

n engl j med 367;26

The authors reply: We agree with Lewis that
limiting the burden on participants and investigators is important in the design of a study. Excessive data collection not only creates more opportunities for missing data, but it can distract
attention from the collection of critical data.
That said, covariate data, auxiliary data, and secondary-outcome data can serve valuable purposes, including improving the ability to understand
and model the missing data.
Hirman and Flyer raise the important issue of
the appropriate intention-to-treat analysis when
patients go off the treatment protocol. We see
three broad options, the relative usefulness of
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